Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022

Fu Der Wang, Phung Anh Nguyen, David Lee, Bulent Taysi, Florence Lefebvre d'Hellencourt, Julia Spinardi, Phan Thanh Phuc, Whitney Burton, Yu-Hui Chang, Nguyen Thi Kim Hien, Shiue Ming Lin, Yang Chieh, Moe H. Kyaw, Jason C. Hsu

研究成果: 雜誌貢獻文章同行評審

摘要

Background: Antivirals are effective in reducing hospitalisation and death in mild-to-moderate coronavirus 2019 (COVID-19) patients. We estimated the antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with a syndrome coronavirus 2 (SARS-CoV-2) infection during the Emergency Use Authorization (EUA) period in Taiwan. Methods: A retrospective cohort study was conducted in Taiwan between January 2022 and December 2022. Patients aged ≥18 years with a SARS-CoV-2 infection were included from the Taipei Medical University Clinical Research Database (TMUCRD) and stratified in three risk groups according to World Health Organization criteria. Results: In total, 96 398 COVID-19 patients (mean age 46.7 ± 17.7 years, 45.8% male) were included. Of these patients 69.8% were classified as low risk, 29.8% as moderate risk, and 0.4% as high risk for progression to severe COVID-19. Nirmatrelvir/ritonavir was prescribed in 5.1% of the COVID-19 patients (low risk = 1.0%, moderate risk = 14.3%, high risk = 17.6%). Molnupiravir was prescribed in 1.9% of the COVID-19 patients (low risk = 0.1%, moderate risk = 5.8%, high risk = 6.9%). Conclusions: Nirmatrelvir/ritonavir and molnupiravir were poorly used in the treatment of adult COVID-19 patients in Taiwan during the pandemic in 2022, especially in moderate-to-high risk groups for progression to severe COVID-19.
原文英語
頁(從 - 到)5032
頁數1
期刊Journal of Global Health
14
DOIs
出版狀態已發佈 - 11月 8 2024

ASJC Scopus subject areas

  • 健康政策
  • 公共衛生、環境和職業健康

指紋

深入研究「Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022」主題。共同形成了獨特的指紋。

引用此